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Abstract
Cisapride (CIS) is a gastrointestinal prokinetic agent. It has been associated with rare, but serious cardiac side effects.
However, it does not affect psychomotor functions or induce central depressant adverse effects. As liquid formulations are
required in a number of cases, an oral suspension of CIS was developed from CIS tablets. The objective of this study was to
investigate the effect of hydroxypropyl--cyclodextrin (HP--CD) on the stability of CIS in oral suspension with an ultimate
aim to formulate a more stable CIS oral suspension. Six batches of CIS oral suspensions, namely, 0 (control), 0.3, 1.6, and 3%
HP--CD containing formulations were prepared. They were stored at 5°C and 30°C. The amounts of CIS in the suspensions
were  determined  by  a  validated  stability-indicating  HPLC-DAD  method.  The  stability  was  assessed  based  on  the  90%
remaining. The changes in the amounts of CIS over time were statistically analyzed by ANOVA and ANCOVA. At 5°C, HP--
CD had no significant effect on the stability of CIS. CIS in all four formulations was stable for at least 12.5 months. At 30°C,
HP--CD affected the stability of CIS. CIS was most stable in 0.3% HP--CD containing formulation with the observed t90 of
approximately 11 months as compared to 7 months in control formulation.
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1. Introduction
Cisapride (CIS), (±)cis-4-amino-5-chloro-N-[1-[3-(4-
fluorophenoxy)propyl]-3-methoxy-4-piperidinyl]-2-methoxy-
benzamide (Figure 1; Merck Index, 1996), is a gastrointestinal
prokinetic agent. It is effective in the treatment of gastroeso-
phageal  reflux  disease  and  non-ulcer  dyspepsia  in  adults,
children, and neonates (McEvoy, 2009; Barone et al., 1994;
Geldof et al., 1993; Reynolds and Putman, 1992; Sweetman,
2005; Wiseman and Faulds, 1994). CIS has been associated
with rare, but serious cardiac side effects including prolonga-
tion of QT interval, torsades de pointes, and sudden cardiac
death, especially when concomitantly administered with
CYP450  3A4  inhibitors  or  in  patients  with  risk  factors  of
cardiac disorders (McEvoy, 2009; Bedford and Rowbotham,
1996; Thomas et al., 1998; Van Haarst et al., 1998; Wysowski
et al., 2001). However, it is largely devoid of central nervous
system depressant or antidopaminergic effects as compared
to  other  prokinetic  agents  such  as  metoclopramide  and
domperidone (McEvoy, 2009; Barone et al., 1994; McCallum,
1996; Wiseman and Faulds, 1994). This medicine, therefore,
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has been withdrawn in some countries, or its use and indica-
tions have been restricted in some countries (World Health
Organization,  2001;  World  Health  Organization,  2003).   In
Thailand, CIS has been severely restricted for prescription
use by gastrointestinal physicians and limited use in gastro-
esophageal reflux disease patients only (World Health Orga-
nization, 2003).
Oral  liquid  formulations  are  needed  in  a  number  of
cases,  e.g.,  to  aid  patients  with  difficulty  in  swallowing
tablets, to allow a more convenient way of adjusting dose for
pediatric patients, and to facilitate the administration of drugs
via nasogastric tube. Therefore, the oral suspension of CIS
is developed from cisapride tablets, the only dosage form
commercially available in some countries such as Thailand.
This formulation is preserved with a combination of methyl-
paraben (MP) and propylparaben (PP), a widely used preser-
vative system in liquid formulations.
CIS is quite unstable in oral liquid formulations (Allen
and Erickson, 1998; Horn and Anderson, 1994; Nahata et al.,
1995), the most stable of which, when stored under refrigera-
tion, was obtained in a mixture of 1% methylcellulose and
simple  syrup  (1:1).  CIS  in  this  formulation  was  stable  for
approximately three months under refrigeration, but only for
one month at 25°C. Allen and Erickson (1998)
 reported that
the stability of CIS can be enhanced by adjusting the pH of
formulation  to  about  7.  In  a  mixture  of  Ora-Sweet
  and
Ora-Plus
 (1:1) adjusted to a pH of 7, CIS was stable for more
than two months under refrigeration and approximately two
months at 25°C (Allen and Erickson, 1998). This might pose
a storage problem in countries located in tropical or warm
climate zones III and IV (Grimm, 1998) where refrigerator is
inevitably needed because of the higher room temperature
(approximately 30°C). To increase the stability of CIS in liquid
formulation, therefore, a stabilizing agent must be added.
Hydroxypropyl -cyclodextrin (HP--CD), a -cyclo-
dextrin derivative, has been shown to stabilize a wide variety
of compounds via inclusion complex formation (Challa et al.,
2005;  Loftsson  and  Brewster,  1996;  Loftson,  1995).  It  has
high water solubility and safety profile for use in systemic
administration, even at high concentration of 40% for intra-
venous injection (Irie and Uekama, 1997; Miyake et al., 1999;
Szente and Szejtli, 1999). Even though -cyclodextrin can also
improve the stability of a number of drugs, it should not be
used for systemic drug formulation due to its low water solu-
bility (1.8% at 25°C) and nephrotoxicity (Kim et al., 2004).
As the complex formation is an equilibrium process,
the  extent  of  complex  formed  depends  upon  cyclodextrin
concentration and inclusion complex formation constant (Kc).
For  a  certain  inclusion  complex  system,  increasing  the
amount of HP--CD will shift the equilibrium to the right, i.e.,
more inclusion complex will be formed. The amount of HP--
CD in liquid formulation can be as high as 40% (Vandewoude
et al., 1997). In this research we investigated the effect of
HP--CD, as well as its concentration, on the stability of CIS
with  an  ultimate  aim  to  formulate  a  more  stable  CIS  oral
suspension.
2. Materials and Methods
2.1 Materials
Cisapride (CIS) and hydroxypropyl--cyclodextrin
(HP--CD, average MW 1460, molar substitution 0.8) were
purchased from Sigma-Aldrich (MO, USA). CIS 5-mg tablets
(CIPASID
®,  Lot  No  969270,  manufacturing  date  12/2006,
expiry date 12/2010) were obtained from Siam Pharmaceutical
Co., Ltd. (Bangkok, Thailand). Pharmaceutical grade methyl-
paraben (MP) and propylparaben (PP) were purchased from
P.C. Drug Center Co., Ltd. (Bangkok, Thailand). Tween 80
was purchased from Srichand United Dispensary Co., Ltd.
(Bangkok, Thailand). Viscocel 681 (microcrystalline cellulose
with  8.3-13.8%  carboxymethylcellulose  sodium)  was
purchased  from  BASF  (Germany).  Acetonitrile,  methanol,
hydrochloric  acid,  and  sodium  hydroxide  were  purchased
from Labscan Co., Ltd. (Bangkok, Thailand). p-Hydroxyben-
zoic acid and sodium-1-pentanesulfonate were purchased
from Fluka (Buchs, Switzerland). Water was obtained using a
Milli-Q water purification system (Millipore Co., MA, USA).
All chemicals were pharmaceutical, analytical or HPLC grade,
and were used without further purification.
2.2 Equipments
All quantitative measurements of CIS were conducted
on an Agilent 1100 series HPLC system (Agilent Technolo-
gies, USA) consisting of a quaternary pump, an autosampler,
and a photo-diode array detector. The system, data acquisi-
tion and processing were performed through Chemstation
software. The separation was performed on a C18 column
(4.6 mm x 150 mm, 5 m, BDS C18, Thermo Electron Corpora-
tion, MA, USA). Peak purity was assessed from photo-diode
array spectral analysis by the instrument software. A Delta
320 pH-meter (Mettler Toledo, Greifensee, Switzerland) was
used for pH determination. The viscosity of the formulations
was measured using a programmable rheometer (Brookfield
DV-III Ultra, Brookfield Engineering, Inc., MA, USA). The
temperature-controlled  water-bath  was  manufactured  by
Scientific Equipment Center, Prince of Songkla University,
Songkhla, Thailand.
2.3 Stability-indicating method
A validated stability-indicating HPLC method for the
determination  of  CIS  in  oral  suspension  was  used.  The
method was based on an ion-paired, reversed phase HPLC
with gradient elution. The mobile phase consisted of solvent
A, which was a mixture of 0.13% sodium-1-pentanesulfonate
pH 8 and acetonitrile (90:10 v/v) and solvent B, which was
acetonitrile. The flow rate of mobile phase was 1.2 mL/min.
The gradient program was as follows: 0-5 min; 20 to 56%
solvent  B;  5-7  min;  56  to  85%  solvent  B;  7-10  min;  85%
solvent B; and re-equilibrated column from 10-13.5 min with
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20 L. The photo-diode array detector was set at 275 nm
with reference in 360 nm and scan mode in the range of 190-
400 nm. The method was validated according to method vali-
dation category I described in USP30 (2007) in the range of
50-120% labeled amount of CIS in oral suspensions. The
following validation characteristics were addressed: system
suitability, selectivity, accuracy, precision, linearity and range.
2.4 Preparation of control formulation of CIS oral suspen-
sion
Six batches of a HP--CD-free control formulation of
1 mg/mL CIS oral suspension were prepared from the powder
of 5-mg CIS tablets according to the formulation published
by  Niazi  (2004)  using  Viscocel  681  as  a  suspending  agent.
A 150 mL suspending vehicle contains Viscocel 681 1.5 g,
Polysorbate 80 75 mg, sucrose 30 g, MP 270 mg, PP 30 mg,
sodium chloride 150 mg and purified water in sufficient quan-
tity to make 150 mL. It was prepared as follows. Viscocel 681
was dispersed and stirred at high speed in 40 mL of purified
water  to  make  a  smooth  dispersion.  MP  and  PP  were  dis-
solved in 30 mL of purified water with the aid of heating to
about  90°C  to  95°C;  sucrose  was  then  dissolved  in  this
solution to give a mixture of syrup and preservatives. This
mixture, after being cooled to room temperature, was added
into Viscocel 681dispersion followed by Polysorbate 80 and
a solution of sodium chloride in 5 mL of purified water while
stirring at high speed. The final volume was adjusted to 150
mL  with  purified  water  and  the  resulting  mixture  was
thoroughly mixed to make a homogenous suspending vehicle.
A 1 mg/mL CIS suspension was prepared by triturat-
ing the powder of 5-mg CIS tablets (30 tablets) with a small
amount  of  the  suspending  vehicle  in  glass  mortar  until
smooth  paste  obtained.  The  three-fourths  portion  of  the
vehicle was then added and homogeneously mixed. The final
volume of 150 mL was adjusted with the vehicle. The initial
pH and viscosity (mean ± SD) of these six batches were 7.5±
0.1 and 42.0±0.06 centipoise, respectively. A 120-mL portion
of each batch was filled into 120-mL polyethylene plastic
prescription bottle with cap.
2.5 Preparation  of  CIS  oral  suspensions  containing  0.3,
1.6, and 3% HP--CD
The 1 mg/mL CIS oral suspensions containing 0.3, 1.6,
and 3% HP--CD, which correspond to the molar ratio of
CIS:HP--CD of 1:1, 1:5, and 1:10, respectively, were prepared
in the same manner as the control formulation by adding the
corresponding  amount  of  HP--CD  into  the  formulations.
Each of these formulations was prepared in six batches and
a 120-mL portion was filled into 120-mL polyethylene plastic
prescription bottles with caps. The initial pH of these pre-
parations (mean ± SD) were 7.5±0.1. The initial viscosities of
0.3, 1.6, and 3% HP--CD containing formulations (mean ±
SD) were 43.2±0.12, 43.2±0.15, and 50.0±0.14 centipoise,
respectively.  The  solubility  of  CIS  in  formulations  was
assessed by directly injecting the clear aqueous supernatant,
after centrifugation, of the suspensions into HPLC system.
2.6 Storage conditions
All six batches of each formulation were stored in the
temperature-controlled water-bath maintained at 30±1°C and
in the refrigerator, the temperature of which ranged from 3°C
to 8°C (median 5°C).
2.7 Study of the stability of CIS in oral suspensions
The amounts of CIS in oral suspensions were deter-
mined,  in  duplicate,  by  the  validated  stability-indicating
HPLC method (Boonleang and Tanthana, 2010) on the day of
preparation (t = 0) and at 0.5, 1, 2, 3, 4, 5.5, 7, 8.5, 10, and 12.5
months. In addition, pH, physical appearance, and redisper-
sibility of all samples were also determined at room tempera-
ture on the day of sample analysis. The redispersibility was
determined by vertically inverting the container by hand and
recording the number of inversions required to resuspend
the sediment completely.
2.8 Data analysis
The remaining amounts of CIS in the various CIS oral
suspensions over time were statistically analyzed by one-
way analysis of variance (ANOVA) and analysis of covari-
ance (ANCOVA) at 95% significance level ( = 0.05) to evalu-
ate the effect of HP--CD at different concentrations, as well
as storage temperatures on the degradation of CIS.
3. Results and Discussion
3.1 Stability-indicating HPLC method
The stability-indicating HPLC method for determina-
tion of CIS in oral suspension was selective, accurate, and
precise. The chromatographic system provided chromato-
grams with good peak shape and acceptable resolution of
CIS, MP, PP, and the degradation products formed in oral
suspensions. CIS peak was pure. All system suitability para-
meters, i.e.; theoretical plates (N), tailing factor (T), and in-
jection repeatability, met the recommended criteria of CDER
reviewer guidance on validation of chromatographic methods
(CDER, 1994). The accuracy ranged from 99.20 to 100.6% of
the true value. The within-run and between-run coefficient
of variations (CV) ranged from 1.11% to 1.38% and from
0.44% to 1.25%, respectively. The calibration curve of CIS
was linear over the concentration range of 10.0-75.0 g/mL
with r
2 > 0.9997. According to these analytical method vali-
dation data, this stability-indicating method for determina-
tion of CIS in oral suspensions was considered reliable and
suitable for the stability study. The representative chromato-
grams of freshly prepared and degraded 1 mg/mL CIS sus-
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3.2 Physical appearance, viscosity, and redispersibility
No significant changes in physical appearance, vis-
cosity, and redispersibility of all formulations stored under
refrigeration were observed for up to 12.5 months. They all
were still in white, easily redispersible suspensions. On the
other hand, changes in color and odor were observed for all
formulations stored at 30°C. A change in color from white to
slightly brown of the control formulation and formulations
containing 0.3, 1.6, and 3% HP--CD was first observed after
storage for 10, 12, 8.5, and 7 months, respectively. However,
the viscosity and redispersibility of all formulations stored at
30°C did not change significantly.
3.3 Changes in pH of CIS oral suspensions
Figure 3 illustrates the changes in pH over time of all
formulations stored at 5°C and 30°C. No significant changes
in pH of all formulations kept at 5°C were observed. When
stored at 30°C, the pH of all formulations decreased. Up to
12.5 months, sigmoid-like decreases in pH approaching the
Figure 2. Representative HPLC chromatograms of freshly prepared
suspension (A) and degraded 1 mg/mL
 CIS suspension
(B). I and II are CIS hydrolysis product I and II, respec-
tively. III, IV and V are unknown degradation products.
Figure 3. Changes in pH (mean ± SEM) over time of various CIS
oral suspensions at 5°C and 30°C.
pH of approximately 3 were observed in control formulation,
1.6%, and 3% HP--CD containing formulations. For 0.3%
HP--CD containing formulation, a trend in pH-decreasing
might also be sigmoid-like shape if the study were continued
further.
3.4 Effect of HP--CD on the stability of CIS in oral suspen-
sions
Figure 4 illustrates the changes in the amount of CIS
over time in control and in HP--CD containing formulations
at 5°C and 30°C. When stored at 5°C, no effect of HP--CD
on the stability of CIS was observed. The ANOVA suggested
that the remaining amounts of CIS in each formulation were
not significantly different (p = 0.69). CIS in all formulations
were stable for at least 12.5 months. The remaining amounts
of CIS in the control formulation and formulations contain-
ing 0.3%, 1.6%, and 3% HP--CD were (mean ± SD) 93.43±
3.58%, 95.29±3.93%, 94.92±3.05%, and 95.99±2.69%, res-
pectively.
When stored at 30°C, CIS in all formulations degraded.
The results from ANCOVA suggested that the degradation
profiles of CIS in each of the formulations were significantly
different (p<0.0001). CIS was most stable in 0.3% HP--CD
containing formulation. The observed t90, i.e., the time at
which a drug has decreased to 90% of its initial amount, of
CIS in control and in 0.3% HP--CD containing formulations
were approximately 7 and 11 months, respectively. During
the first 120 days the degradation rates of CIS in all formula-
tions were slower than later. This observation corresponded
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tion rate of CIS was increased when the pH of formulation
was lower than 7. The feasible degradation pathway of CIS
might  be  hydrolysis,  as  shown  in  Figure  5.  An  acidic  CIS
hydrolysis product I was produced, which lowered the pH of
formulations and further accelerated hydrolysis of CIS. p-
Hydroxybenzoic acid, the hydrolysis degradation product of
MP and PP (Connors et al., 1986) also lowers the pH of the
formulation. However, since the initial pH decreasing rate of
control  formulation  was  slower  than  that  of  1.6%  and  3%
HP--CD containing formulations, it was most likely that the
difference in pH-decreasing rate observed in different formu-
lations  was  from  the  hydrolysis  of  CIS.  In  addition,  the
suspension excipients, as well as the tablet excipients from
CIS tablets used to prepare the suspensions in this study
might have some contributions on the degradation of CIS.
This was probably evident from the presence of unknown
degradation peaks in the chromatogram of degraded suspen-
sion (Figure 2).
Cyclodextrins can form in-situ inclusion complexes
with a number of drugs in aqueous media and hence increase
drug solubility even when there is no complexation in solid
state (Higuchi et al., 1965; Rasheed et al., 2008). The inclu-
sion complex formation between CIS and HP--CD might be
evident from the increasing solubility of CIS as the concen-
tration of HP--CD in formulation increased.
0.3% HP--CD containing formulation increased the
stability of CIS as compared to control formulation. However,
increasing the concentration of HP--CD decreased CIS sta-
bility. This suggests that the less stable inclusion complex
between CIS and HP--CD was formed at higher HP--CD
concentration. This might be the same situation as the inclu-
sion complex formation between CIS and -cyclodextrin (-
CD) reported by Omari et al. (2007). In this case, CIS forms
1:1 and 1:2 CIS:-CD inclusion complexes. In 1:1 CIS:-CD
complex,  the  hydrolysis-sensitive  amide  bond  of  CIS  is
completely included into the -CD cavity whereas in 1:2 CIS:
-CD complex the amide bond is located between the wider
rims of two -CD molecules outside their cavities. Therefore,
the 1:1 CIS:-CD inclusion complex is more stable to hydro-
lysis than the 1:2 CIS:-CD inclusion complex. The same is
very likely true for the inclusion complex formation between
CIS and HP--CD as the chemical structures of HP--CD and
-CD are very similar (El-Barghouthi et al., 2006; Peeters et
al., 2002). At low concentration of HP--CD, the more stable
1:1 CIS:HP--CD complex is mostly formed, but at high con-
centration, the less stable 1:2 CIS:HP--CD complex is mostly
formed. When compared to free CIS, the destabilizing effect
of  HP--CD  on  the  stability  of  CIS  in  1:2  CIS:HP--CD
complex might be attributable to the decreased entropy of
CIS in the above mentioned complex. Scheme 1 shows the
proposed degradation pathway of CIS in HP--CD contain-
ing formulation.
CIS + HP--CD
CIS-HP--CD
k0
degradation products
degradation products
HP--CD-CIS-HP--CD
degradation products
KC 1:2 KC 1:1
kc 1:1 kc 1:2
Scheme 1 Degradation pathway of CIS in HP--CD contain-
ing formulation.
Figure 4. % CIS remaining (mean ± SEM) over time in various CIS
oral suspensions at 5°C and 30°C. The profiles at 5°C are
not significantly different (p = 0.69). The profiles at 30°C
are significantly different (p < 0.0001).
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Where KC 1:1 and KC 1:2 are the inclusion complex formation
constants of 1:1 and 1:2 CIS-HP-b-CD complex, respectively;
k0 is the degradation rate constant of uncomplexed CIS; kc 1:1
and kc 1:2 are the degradation rate constants of CIS from 1:1
and from 1:2 CIS-HP--CD complexes, respectively.
The observed degradation rate constant (kobs) is a
weighted  average  of  all  corresponding  rate  constants  as
shown in the equation below:
2 : 1 c 2 : 1 C 1 : 1 c 1 : 1 C 0 f obs k F k F k F k   
where Ff, FC 1:1, and FC 1:2 are the mole fractions of uncom-
plexed CIS, 1:1, and 1:2 CIS-HP--CD complexes, respect-
ively. The data obtained in this study apparently supported
that  the  relative  degradation  rate  constant  could  be  as
follows: kc 1:1 < k0 < kc 1:2. In 0.3% HP--CD containing formu-
lation where CIS was mostly in the more stable 1:1 CIS:HP--
CD complex, therefore, the degradation of CIS was slower
than in control formulation. On the other hand, in 1.6% and
3%  HP--CD  containing  formulations,  most  of  CIS  was
increasingly in an unprotected 1:2 CIS:HP--CD complex,
therefore, the increase in CIS degradation rate was observed.
Even though CIS degradation rate constant is pH-dependent
with higher rate at pH < 7, the relative magnitude of k0, kc 1:1,
and kc 1:2 was unchanged. As a result, CIS in all formulations
degraded with faster rate after 120 days of storage correlated
with the lower in pH of formulations.
4. Conclusion
CIS in the studied suspensions was more stable when
stored at 5°C than at 30°C. At 5°C HP--CD had no signifi-
cant effect on the stability of CIS. CIS in all formulations was
stable for at least 12.5 months. At 30°C, HP--CD had an
effect on the stability of CIS. CIS was most stable in formula-
tion containing 0.3% HP--CD, which corresponds to 1:1
CIS:HP--CD  molar  ratio.  The  observed  t90  of  CIS  in  this
formulation was approximately 11 months. Increasing the
concentration  of  HP--CD  in  formulation  decreased  the
stability of CIS.
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